ContractExclusive Global License Agreement • December 10th, 2024
Contract Type FiledDecember 10th, 2024Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions